Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Flexion Therapeutics, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

Flexion Therapeutics focuses on the development of innovative non-opioid therapies for the treatment of patients with osteoarthritis.

Metric
Company Name	Flexion Therapeutics, Inc.	Ardelyx, Inc.
Symbol	FLXN	ARDX
MSH ID	COM:FLEXIONTHERAPEUTICS	COM:ARDELYX
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Biotechnology
Country	US	US
Stage		Debt
Employee Count	257	267
Website	flexiontherapeutics.com	ardelyx.com
LinkedIn
Founders

Metric
Market Cap		1.30B
Enterprise Value
Monthly Web Traffic	47	33.50K
Web Traffic Growth	24.04	2.80
Valuation
Raised Capital	30M	20M

Metric
Revenue		124.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit		106.66M
EBITDA		-55.35M
Operating Income		-63.28M
Net Income		-66.07M
EPS		-0.30
Diluted EPS		-0.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.86
Operating Profit Margin		-0.28
EBITDA Margin		-0.44
Net Profit Margin		-0.31
Return on Equity		-0.40
Return on Assets		-0.19
Return on Capital Employed		-0.21

FLXN

COM:FLEXIONTHERAPEUTICS

Flexion Therapeutics

Last Close

9.12

01/01 00:00

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-74.58
P/B Ratio		10.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		14.47
EV Multiple		-20.25

Metric
Days Sales Outstanding		117.61
Days Payables Outstanding		185.33
Days Inventory Outstanding		264.91
Operating Cycle		329.52
Cash Conversion Cycle		100.07
Asset Turnover		0.61

Metric
Operating Cash Flow		-89.72M
Free Cash Flow		-90.06M
Cash Flow to Debt		-0.77
Operating Cash Flow/Sales		-0.41
Free Cash Flow Yield		-0.03

Metric
Cash & Equivalents		21.47M
Accounts Receivable		-14.30M
Inventory		12.45M
Goodwill
Debt to Capitalization		0.41
Debt to Assets		0.12
Current Ratio		5.54
Quick Ratio		4.36

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.09
R&D to Revenue		0.26
SG&A to Revenue		0.15